HC Wainwright Has Positive Outlook for RLAY Q1 Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Relay Therapeutics in a research note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.49) EPS.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $4.34 million.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Guggenheim upped their target price on Relay Therapeutics from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Wells Fargo & Company raised their target price on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 17th. Citizens Jmp lifted their target price on Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a report on Tuesday, March 17th. Finally, Oppenheimer reissued an “outperform” rating on shares of Relay Therapeutics in a research note on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Relay Therapeutics Trading Down 3.9%

Shares of RLAY opened at $9.44 on Wednesday. The firm’s fifty day simple moving average is $8.98 and its two-hundred day simple moving average is $7.54. Relay Therapeutics has a 12 month low of $1.77 and a 12 month high of $11.49. The stock has a market capitalization of $1.69 billion, a P/E ratio of -5.83 and a beta of 1.55.

Insider Activity at Relay Therapeutics

In other news, insider Peter Rahmer sold 11,684 shares of the stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08. Following the transaction, the insider owned 277,964 shares of the company’s stock, valued at $2,118,085.68. This represents a 4.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Thomas Catinazzo sold 13,820 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $105,308.40. Following the completion of the sale, the chief financial officer owned 250,996 shares of the company’s stock, valued at approximately $1,912,589.52. This represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 93,302 shares of company stock worth $724,355 over the last three months. 4.32% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Relay Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its holdings in shares of Relay Therapeutics by 130.4% in the 2nd quarter. Franklin Resources Inc. now owns 394,122 shares of the company’s stock worth $1,364,000 after purchasing an additional 223,042 shares in the last quarter. Congress Asset Management Co. increased its stake in Relay Therapeutics by 160.9% during the 3rd quarter. Congress Asset Management Co. now owns 408,842 shares of the company’s stock valued at $2,134,000 after purchasing an additional 252,142 shares in the last quarter. Geode Capital Management LLC increased its stake in Relay Therapeutics by 5.2% during the 2nd quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock valued at $11,176,000 after purchasing an additional 159,548 shares in the last quarter. Commodore Capital LP raised its holdings in Relay Therapeutics by 27.3% during the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after buying an additional 3,650,000 shares during the last quarter. Finally, Bellevue Group AG raised its holdings in Relay Therapeutics by 11.6% during the second quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock worth $28,479,000 after buying an additional 853,578 shares during the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.